Archive for September 2023
Longitudinal Efficacy and Safety Modeling and Simulation Framework to Aid Dose Selection of Belantamab Mafodotin for Patients with Multiple Myelo.
Collins J., Noort van M., Rathi C., Post T.M., Struemper H., Jewell R.C., FerronBrady G. Longitudinal Efficacy and Safety Modeling and Simulation Framework to Aid Dose Selection of Belantamab Mafodotin for Patients with Multiple Myelo. CPT Pharmacometrics Syst. Pharmacol. 2023 [Link to publication].
Read MoreExtended use of levonorgestrel-releasing intrauterine system (LNG-IUS) 52 mg: A population pharmacokinetic approach to estimate in vivo levonorgestrel release rates and systemic exposure including comparison with two other LNG-IUSs.
Jensen J.T., Reinecke I., Post T.M. , Lukkari-Lax E. , Hofmann B.M, Extended use of levonorgestrel-releasing intrauterine system (LNG-IUS) 52 mg: A population pharmacokinetic approach to estimate in vivo levonorgestrel release rates and systemic exposure including comparison with two other LNG-IUSs. Contraception, 2023. [Link to publication].
Read MoreEvaluation of a Cardiovascular Systems Model for Design and Analysis of Hemodynamic Safety Studies
Fu Y., Snelder N., Guo T., Graaf van der P.H., Hasselt J.G.C. Evaluation of a Cardiovascular Systems Model for Design and Analysis of Hemodynamic Safety Studies. Pharmaceutics, 2023 [Link to publication].
Read MorePopulation pharmacokinetics of riociguat in a pediatric population (aged ≥ 6 years) with pulmonary arterial hypertension.
Willmann S., Keller A.K., Meyer M., van der Mey D., Wirsching G., Zhang Y., Drenth H., Keunecke A., Vendel E. Population pharmacokinetics of riociguat in a pediatric population (aged ≥ 6 years) with pulmonary arterial hypertension. Pediatiric Pulmonology, 2022. [Link to publication].
Read MoreModel-informed bridging of rivaroxaban doses for thromboprophylaxis in pediatric patients with congenital heart disease aged 9 years and above.
Willmann S., Ince I, Ahsman M., Coboeken K., Zhang Y., Thelen K., Kubitza D., Zannikos P., Zhou W., Pina L., Post T., Lippert J. Model-informed bridging of rivaroxaban doses for thromboprophylaxis in pediatric patients with congenital heart disease aged 9 years and above. CPT: pharmacometrics & systems pharmacology, p001-011, 2022. [Link to publication].
Read More